Immuneering
Cambridge, Massachusetts, United States · Biotechnology, Healthcare, Health Care
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-d
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (IMRX)
- Website
- immuneering.com
- Company page
Recent activity at Immuneering
- : Grant C. Bogle Appointed as Class III Director at Immuneering Corporation
- : Immuneering
- : Igor Matushansky, MD, PhD, Joins Immuneering as Chief Medical Officer
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Employee benefit plans
Immuneering files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About Immuneering: questions and answers
What does Immuneering do?
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-d
Where is Immuneering headquartered?
Immuneering is headquartered in Cambridge, Massachusetts, United States.
What is the latest news on Immuneering?
On Nov 9, 2026, Grant C. Bogle Appointed as Class III Director at Immuneering Corporation
Is Immuneering a public company?
Yes. Immuneering is publicly traded under the ticker IMRX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy